Quantcast

To friend or not to friend? That is the FDA question

How closely can nutritional supplement companies connect with the fast-moving world of social media? The FDA will address these questions at a hearing Nov. 12-13 in Washington. The agency is soliciting comments in the Federal Register.

Orlistat and Hydroxycut: Similar health problems, but comparable FDA treatment?

This is a tale of two types of weight-loss products and how the Food and Drug Administration had different responses to similar problems with them. The separate, but not equivalent treatment raises questions about how the FDA operates.

Hydroxycut: Hype and reality

In the days following the FDA warning on the dangers of taking Hydroxycut and the manufacturer’s recall, the reaction has been more sliced than divided. There were the oft-seen reactions: NaturalNews headlined its commentary, “FDA Floats Hydroxycut Scare to Discredit Yet Another Supplement Company.”  The personal injury law firm of Onder Shelton O’Leary & Peterson [...]

FDA needs more resources, but for more regulation of dietary supplements?

When it comes to dietary supplements, it’s like the Wild West, and the bad guys know they don’t have to take the sheriff seriously.
Industry and consumer voices are split in their interpretations of a GAO report on how the FDA should regulate dietary supplements. All sides agree that the FDA needs more resources, but they [...]

Adverse Event Reporting (AER) Label Compliance

Although Section 403(y) of the Federal Food, Drug, and Cosmetic Act (FFD&C Act) (21 U.S.C. 343(y), does not require a dietary supplement label to include anything other than a domestic address or phone number for the responsible person, the FDA recommends that the label also bear a clear, prominent statement informing consumers that [...]